| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| 靶点 |
TRPV4 agonist-1 targets transient receptor potential vanilloid 4 (TRPV4) with an EC₅₀ value of 1.8 μM in calcium influx assay [1]
|
|---|---|
| 体外研究 (In Vitro) |
TRPV4 激动剂-1(化合物 36)表现出明显更高的效力(ECmax:在 SOX9 报告基因测定中为 20 nM)。 TRPV1 通道不被 TRPV4 激动剂 1 占用 [1]。
用TRPV4 agonist-1(1–10 μM)处理原代大鼠关节软骨细胞,呈剂量依赖性上调软骨形成标志物COL2A1、SOX9和ACAN的mRNA表达,同时下调分解代谢标志物MMP13的表达 [1] - 在5 μM浓度下,TRPV4 agonist-1 可显著增强软骨细胞中II型胶原蛋白的合成,Western blot检测结果证实了这一效应 [1] - TRPV4 agonist-1(10 μM)可抑制IL-1β诱导的软骨细胞NF-κB激活,表现为IκBα和p65的磷酸化水平降低 [1] |
| 体内研究 (In Vivo) |
在手术诱导的大鼠骨关节炎(OA)模型(前交叉韧带切断+内侧半月板切除术)中,关节内注射TRPV4 agonist-1(10 μg/关节,每周1次,连续4周),与溶媒对照组相比,可显著减少软骨侵蚀,降低骨关节炎研究学会国际(OARSI)评分 [1]
- TRPV4 agonist-1 治疗可降低OA大鼠滑膜炎症,表现为滑液中TNF-α和IL-6水平下降 [1] - 显微CT和组织学染色结果显示,该药物可维持关节软骨厚度,减少OA大鼠软骨下骨硬化 [1] |
| 酶活实验 |
钙内流实验:软骨细胞负载钙敏感荧光染料后,与系列稀释的TRPV4 agonist-1 共同孵育,实时检测荧光强度,以确定反映TRPV4激活的EC₅₀值 [1]
- NF-κB荧光素酶实验:转染NF-κB荧光素酶报告质粒的软骨细胞,先用TRPV4 agonist-1 预处理,再经IL-1β刺激,通过检测荧光素酶活性评估NF-κB的抑制情况 [1] |
| 细胞实验 |
原代大鼠关节软骨细胞分离:从大鼠膝关节获取关节软骨,经胶原酶消化后,在软骨形成培养基中培养,取第二代细胞用于实验 [1]
- mRNA表达分析:软骨细胞经TRPV4 agonist-1 处理48小时后,提取总RNA并逆转录为cDNA,通过实时荧光定量PCR检测COL2A1、SOX9、ACAN和MMP13的mRNA水平 [1] - Western blot分析:药物处理后的软骨细胞经裂解后,提取蛋白质进行SDS-PAGE电泳,转膜后用II型胶原蛋白、磷酸化IκBα和磷酸化p65抗体进行孵育,通过密度分析法对条带强度进行定量 [1] |
| 动物实验 |
OA model establishment: Male Sprague-Dawley rats (200–250 g) underwent anterior cruciate ligament transection and medial meniscectomy under anesthesia to induce OA [1]
- Drug formulation: TRPV4 agonist-1 was dissolved in dimethyl sulfoxide (DMSO) and further diluted with phosphate-buffered saline (PBS) to a final DMSO concentration of ≤5% [1] - Administration protocol: Rats were randomly divided into vehicle control and drug-treated groups. TRPV4 agonist-1 was administered via intra-articular injection at a dose of 10 μg/joint once weekly for 4 weeks, starting 1 week after surgery [1] - Sample collection: At the end of treatment, rats were euthanized, knee joints were harvested for histological analysis and micro-CT scanning, and synovial fluid was collected for cytokine detection [1] |
| 毒性/毒理 (Toxicokinetics/TK) |
In vitro toxicity: TRPV4 agonist-1 showed no significant cytotoxicity in primary chondrocytes at concentrations up to 20 μM, as determined by CCK-8 assay [1]
- In vivo toxicity: No obvious systemic toxicity (such as weight loss, abnormal behavior, or organ damage) was observed in OA rats treated with TRPV4 agonist-1 during the 4-week study period [1] |
| 参考文献 | |
| 其他信息 |
TRPV4 agonist-1 is a quinazolin-4(3H)-one derivative designed as a selective TRPV4 agonist [1]
- The drug exerts chondroprotective effects by activating TRPV4, which in turn promotes chondrogenic differentiation and inhibits catabolic and inflammatory responses in chondrocytes [1] - The in vivo study demonstrated that TRPV4 agonist-1 has potential therapeutic value for the treatment of osteoarthritis [1] |
| 分子式 |
C25H22F2N4O2
|
|---|---|
| 分子量 |
448.464592456818
|
| 精确质量 |
448.171
|
| CAS号 |
2314467-59-7
|
| PubChem CID |
137628676
|
| 外观&性状 |
White to off-white solid powder
|
| LogP |
4
|
| tPSA |
48.4
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
6
|
| 可旋转键数目(RBC) |
4
|
| 重原子数目 |
33
|
| 分子复杂度/Complexity |
713
|
| 定义原子立体中心数目 |
0
|
| SMILES |
FC1=CC=CC2=C1N=C(N(C1C=CC(=CC=1)OC1C=CC(=CC=1)F)C2=O)N1CCN(C)CC1
|
| InChi Key |
NUGPMKZYSBKNPU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H22F2N4O2/c1-29-13-15-30(16-14-29)25-28-23-21(3-2-4-22(23)27)24(32)31(25)18-7-11-20(12-8-18)33-19-9-5-17(26)6-10-19/h2-12H,13-16H2,1H3
|
| 化学名 |
8-fluoro-3-[4-(4-fluorophenoxy)phenyl]-2-(4-methylpiperazin-1-yl)quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~83.33 mg/mL (~185.81 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.08 mg/mL (4.64 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 20.8 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2299 mL | 11.1493 mL | 22.2985 mL | |
| 5 mM | 0.4460 mL | 2.2299 mL | 4.4597 mL | |
| 10 mM | 0.2230 mL | 1.1149 mL | 2.2299 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。